How to Lower Your DHT Levels While on TRT

Switching your TRT delivery method and adding a 5-alpha reductase inhibitor are the two most effective levers for reducing dihydrotestosterone while staying on testosterone replacement therapy. DHT rises on every form of TRT, but the magnitude depends heavily on the route of administration, and pharmaceutical blockers can slash circulating DHT by half or more. The practical challenge is that DHT is not purely a nuisance hormone, so any strategy to lower it involves trade-offs worth understanding before you commit.

Why DHT Climbs on TRT in the First Place

Your body converts a portion of every testosterone dose into DHT through an enzyme called 5-alpha reductase. There are two main versions of this enzyme distributed across different tissues, including the skin, scalp, prostate, and liver. When you introduce exogenous testosterone, more substrate is available for conversion, and DHT levels rise accordingly. The degree of that rise is not fixed; it depends on your genetics, the dose, and how the testosterone enters your bloodstream.

The delivery route makes a surprisingly large difference. A systematic review and meta-analysis found that transdermal TRT (gels and patches) elevated DHT roughly 5.5-fold above baseline, while intramuscular injections raised it about 2.2-fold.¹ That is a substantial gap. Gel formulations deliver testosterone through the skin, where 5-alpha reductase activity is high, so more conversion happens at the site of absorption before the hormone even reaches general circulation. Injections bypass the skin entirely and produce a DHT increase that roughly mirrors the testosterone increase.

If you are currently using a gel or patch and your DHT is running high, switching to intramuscular or subcutaneous injections is often the simplest first step. It will not eliminate the DHT rise, but it can cut the excess roughly in half without adding any medication. A separate study comparing testosterone gel and injectable testosterone undecanoate noted that gels can push DHT up to 300% above baseline, with injectables producing a broadly similar range of 200–300%, though the meta-analytic data suggest injectables tend to land on the lower end of that spread.²

Finasteride and Dutasteride on TRT

When a route change alone is not enough, 5-alpha reductase inhibitors are the standard pharmaceutical option. Finasteride blocks the type 2 isoenzyme, which is the dominant form in the prostate and reproductive tissues. Dutasteride blocks both type 1 and type 2, casting a wider net across the body. Because of that dual action, dutasteride reduces serum DHT more aggressively than finasteride.³

In the context of TRT specifically, these drugs have been studied directly. A trial of older hypogonadal men receiving testosterone plus finasteride found that finasteride completely prevented the prostate volume increase caused by testosterone, while preserving the musculoskeletal and body-composition benefits of the TRT itself.⁴ That last part matters: the men still gained lean mass and lost fat on TRT even though their DHT was suppressed, suggesting that testosterone itself (rather than DHT) drives those outcomes.

Dutasteride paired with TRT tells a similar story for the prostate. In a study of hypogonadal men with benign prostatic hyperplasia, those receiving testosterone plus dutasteride saw their prostate volume shrink by about 12% and their PSA drop by roughly 35%, while the testosterone-only group had a small (non-significant) increase in prostate volume and a significant PSA rise.⁵ For men whose prostate health is the primary concern driving their desire to lower DHT, this combination has direct clinical evidence behind it.

The Side-Effect Conversation Around 5AR Inhibitors

Finasteride and dutasteride are not side-effect-free, and the risks are worth weighing honestly against the benefits. The most commonly discussed concerns fall into two categories: sexual function and mood.

On the sexual side, the fear is that lowering DHT will kill libido or cause erectile problems. Some men do report these effects, but the picture is not as straightforward as online forums suggest. A placebo-controlled trial that gave pure DHT (not testosterone) to healthy older men for 24 months found that DHT administration had essentially no effect on 33 measures of sexual function and mood, apart from a mild decrease in overall sexual desire that reversed after stopping treatment.⁶ That study was looking at adding DHT rather than blocking it, but it suggests DHT’s role in sexual function may be more modest than assumed, especially when testosterone itself remains at healthy levels, as it does on TRT.

The mood side is where newer research raises more genuine concern. Finasteride does not only block the conversion of testosterone to DHT; it also interferes with the production of allopregnanolone, a neurosteroid involved in mood regulation. Preclinical work has linked finasteride to depression-like behavior and impaired neurogenesis, effects attributed to depleted allopregnanolone rather than to low DHT itself.⁷ That same research found that newer experimental 5-alpha reductase inhibitors could block DHT production without affecting allopregnanolone, which points toward future drugs that might separate the desired effect from the mood risk. For now, though, the drugs available are finasteride and dutasteride, and the neurosteroid issue is real enough to discuss with your prescriber, especially if you have a history of depression or anxiety.

Topical Finasteride as a Targeted Option

If your main reason for wanting lower DHT is hair loss rather than prostate protection, topical finasteride offers a way to reduce DHT at the scalp while limiting systemic exposure. A phase III trial comparing topical finasteride spray to oral finasteride found that the topical version lowered serum DHT by about 35%, compared to roughly 56% with the oral pill.⁸ Maximum blood levels of finasteride were over 100 times lower with the topical formulation, which in theory reduces the likelihood of the sexual and mood side effects linked to systemic DHT suppression.

A smaller pharmacokinetic study explored different topical finasteride doses and found that lower volumes reduced serum DHT by only about 25%, while higher volumes approached 45–50% suppression. Scalp DHT dropped significantly at all doses tested.⁹ So even with topical application, some systemic DHT lowering occurs; it is a matter of degree, not an on/off switch. A systematic review of topical finasteride studies confirmed that both scalp and plasma DHT decrease, with no changes in serum testosterone.¹⁰

For someone on TRT who wants to protect their hairline but is not worried about prostate size, topical finasteride hits a practical middle ground. You get meaningful DHT reduction where it matters most for hair, with less systemic suppression than a daily oral pill. It is not a perfect separation, but it is a real one.

Saw Palmetto and Other Natural Approaches

Saw palmetto extract is the most commonly cited botanical 5-alpha reductase inhibitor, and the evidence is mixed enough to be worth parsing carefully. A 16-week randomized, placebo-controlled trial of a standardized saw palmetto oil found that oral supplementation significantly reduced serum DHT compared to placebo, while topical application did not.¹¹ That sounds promising, but an older head-to-head comparison of saw palmetto (Permixon brand) and finasteride in healthy men found that saw palmetto had no measurable effect on serum DHT levels.¹²

The disagreement likely comes down to the specific extract and dose. Not all saw palmetto preparations are equivalent, and the standardization of active compounds varies widely between products. If you want to try saw palmetto as a supplement alongside TRT, go in with realistic expectations: some formulations may produce a modest DHT reduction, but the effect will be far smaller and less reliable than what you would get from finasteride or dutasteride. Treat it as a gentle nudge, not a replacement for pharmaceutical options.

Green tea catechins have also shown 5-alpha reductase inhibition in laboratory settings. Epigallocatechin-3-gallate (EGCG) inhibits the type 1 enzyme specifically, and animal studies have shown it can reduce androgen-dependent tissue growth.¹³ Translating that to meaningful serum DHT reduction in a person on TRT is a much bigger leap. There are no clinical trials showing that drinking green tea or taking EGCG supplements meaningfully lowers DHT in men on testosterone therapy. It is worth mentioning because it comes up frequently in online discussions, but the honest assessment is that the evidence stays in the lab for now.

What You Lose When You Lower DHT

DHT is often framed purely as a problem, the hormone behind hair loss, prostate growth, and oily skin. But it has legitimate functions, and suppressing it is not free of trade-offs beyond the side-effect risks already discussed.

In muscle tissue, DHT appears to play a distinct role that testosterone alone does not fully replicate. Mouse skeletal muscle research found that DHT significantly boosted amino acid uptake in fast-twitch muscle fibers, with an increase of nearly 90% for one amino acid marker, while testosterone at the same concentration had no measurable effect on uptake in either fiber type.¹⁴ This was an in-vitro study on mouse tissue, not a clinical trial in humans, so the direct practical relevance is uncertain. Still, it suggests that blocking DHT entirely could blunt some anabolic signaling in fast-twitch muscle. The clinical trial that combined TRT with finasteride did not find a difference in lean mass gains, which is reassuring for most purposes, but the question of whether very high-performance or strength-focused individuals might notice a difference remains open.

Data from the Testosterone Trials showed that men whose DHT rose more during 12 months of testosterone treatment experienced larger increases in hemoglobin and sexual desire compared to men with smaller DHT increases.¹⁵ Bone mineral density changes were also more robustly associated with rising estradiol and DHT. These associations do not prove that lowering DHT will reverse those benefits, since testosterone and estradiol are both still present on TRT, but they do suggest that some of the gains men attribute to TRT may be partly DHT-mediated.

Hematocrit and the Red Blood Cell Question

One side effect of TRT that many men hope to manage by lowering DHT is elevated hematocrit, the proportion of blood made up of red blood cells. A higher hematocrit can increase the risk of blood clots and is one of the most common reasons men on TRT need dose adjustments or blood donations. Because DHT is a potent androgen, there is an intuitive assumption that blocking it would help keep hematocrit in check.

The evidence is not as encouraging as you might hope. A controlled trial that combined graded testosterone doses with dutasteride found that hemoglobin and hematocrit rose in a dose-dependent fashion related to testosterone levels, and the changes did not differ significantly between the dutasteride and placebo groups.¹⁶ In other words, even complete dual 5-alpha reductase blockade did not prevent the red-blood-cell increase from testosterone. If hematocrit is your primary concern, lowering DHT is unlikely to solve the problem. Dose reduction, more frequent injections to avoid peaks, or therapeutic phlebotomy remain the main tools.

Monitoring DHT and Adjusting Your Approach

Most standard TRT bloodwork panels do not include DHT unless you specifically request it. If you are experiencing symptoms that could be DHT-related, such as accelerating hair loss, prostate symptoms, or severe acne, asking for a serum DHT level gives you a useful data point. The ratio of testosterone to DHT can also be informative. An older study found that the T/DHT ratio is primarily a function of testosterone levels rather than an independent marker, and that in some elderly men with low testosterone but already-high DHT, starting testosterone therapy actually brought DHT down as the ratio normalized.¹⁷ This is a reminder that DHT does not always go up on TRT; individual biology introduces real variability.

If you do add a 5-alpha reductase inhibitor, rechecking DHT a couple of months later confirms that the drug is working. For dutasteride users, it is worth noting that the drug has a very long half-life, on the order of weeks, so effects (and side effects) build gradually and also take a long time to wash out if you stop. Finasteride clears faster, which gives you a shorter feedback loop.

PSA monitoring deserves a mention because 5-alpha reductase inhibitors artificially lower PSA readings. The dutasteride-TRT study noted a 35% PSA drop in the treatment group, which is clinically useful for men with benign prostate growth but creates a wrinkle for cancer screening: a “normal” PSA on dutasteride may actually be masking a value that would have triggered further evaluation without the drug. Any clinician monitoring your prostate health needs to know you are on a 5AR inhibitor so they can adjust their interpretation.

Topical Androgen Receptor Blockers

A completely different strategy from lowering DHT production is blocking DHT from binding at the receptor level, at least locally. Research compounds like RU58841 have shown potent androgen receptor antagonism in both cell and animal models, with evidence of topical anti-hair-loss effects in primates.¹⁸ These compounds do not reduce circulating DHT at all; they block the receptor in the skin or scalp where they are applied.

RU58841 has never been approved for human use and is not available through any pharmacy. It circulates in the gray market of research-chemical vendors, and people who use it are essentially self-experimenting with an unregulated substance. The lack of human safety data, particularly around long-term systemic absorption or liver effects, makes this a riskier option than the pharmaceuticals described above. It is worth knowing that the concept exists, and that approved topical antiandrogens may eventually reach the market, but for now this category sits firmly in the experimental column.

Genetic Variation in 5-Alpha Reductase Activity

Not everyone converts testosterone to DHT at the same rate. The gene encoding the type 2 5-alpha reductase enzyme (SRD5A2) has dozens of known variants across populations worldwide. A global review identified over 400 cases of clinically significant 5-alpha reductase type 2 deficiency, with the majority involving missense variants that reduce or eliminate enzyme function.¹⁹ Full deficiency is rare, but partial variation in enzyme efficiency is likely much more common and could explain why some men on TRT experience dramatic DHT-related symptoms while others on the same protocol do not.

This genetic variability also means that the same dose of finasteride or dutasteride may produce different degrees of DHT suppression in different people. If you are a high converter (naturally elevated DHT relative to your testosterone level), you may need a more aggressive approach. If you are a low converter, your DHT might not be particularly elevated on TRT in the first place, and adding a 5AR inhibitor may be solving a problem you do not have. Checking your actual DHT level before starting any intervention saves you from unnecessary medication and its associated risks.